Muzzey Dale 4

What Happened

• Dale Muzzey, Chief Scientific Officer of Myriad Genetics (MYGN), received a grant of 173,196 restricted stock units (RSUs) on 2026-03-12 (reported as an acquisition at $0.00).
• To satisfy tax withholding when portions vested, the issuer withheld a total of 37,799 shares across 2026-03-13 to 2026-03-15 at $4.66 per share, totaling approximately $176,143. These withholding transactions are reported as "F" (payment of exercise price or tax liability) and are routine tax-related dispositions rather than open-market sales.

Key Details

• Grant: 173,196 RSUs on 2026-03-12 (code A) — reported acquisition price $0.00.
• Withholdings (code F): 12,779 shares on 2026-03-13 ($4.66, $59,550); 8,288 shares on 2026-03-14 ($4.66, $38,622); 4,783 shares on 2026-03-15 ($4.66, $22,289); 11,949 shares on 2026-03-15 ($4.66, $55,682). Total withheld: 37,799 shares, ~$176,143.
• Footnotes: F1 — RSUs are time-based and vest in three equal annual installments (2017 Equity Plan). F2/F3 — shares were withheld by the issuer to satisfy tax withholding for time-based and performance-based RSUs, using the closing price on March 13, 2026.
• Shares owned after the transactions are not provided in the data shown.
• Filing date: 2026-03-16; filing appears to be within the normal Form 4 timing window for these transactions.

Context

• RSUs represent a contingent right to receive shares upon vesting; the grant itself is not a market purchase or sale. The withheld-share transactions are a common, administrative cashless way to meet tax obligations when RSUs vest and do not necessarily signal the insider's view of the company's stock.